Opendata, web and dolomites

SupraRNA SIGNED

A Comprehensive Supramolecular Approach for an RNA vaccine for Influenza A (H1N1)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SupraRNA project word cloud

Explore the words cloud of the SupraRNA project. It provides you a very rough idea of what is the project "SupraRNA" about.

functionalized    transfection    glycol    groundwork    aryl    seasonally    pr8    enzymatic    threat    employed    strain    hydrophilic    nature    protect    environments    parts    peptide    promise    connected    circulate    declared    intracellular    health    assemblies    oligo    decorated    viruses    seasonal    model    gene    influenza    nucleic    conjugation    incorporation    acids    efficacy    globally    afforded    poly    rna    acute    hemagglutinin    virus    co    prevention    hydrogen    lay    mrna    peg    pi    covalent    vector    messenger    molecule    immense    stabilization    strand    redox    nanoassembly    respiratory    surface    scope    exploring    pathogens    assembly    therapeutic    manufacturing    amphiphile    macrophage    vaccination    chain    oxy    biological    vaccines    bond    disease    hydrolysis    disulfide    central    efficient    healthcare    tat    steric    world    alternatively    supramolecular    enhanced    times    self    epidemic    lines    infection    optimum    chains    ethylene    h1n1    class    transport    caused    cell    responsive    bonding    vehicle    groups    moiety    platform    persistent   

Project "SupraRNA" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF BIRMINGHAM 

Organization address
address: Edgbaston
city: BIRMINGHAM
postcode: B15 2TT
website: www.bham.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 212˙933 €
 EC max contribution 212˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) coordinator 212˙933.00

Map

 Project objective

*The development of vaccines is key for disease prevention, and is a major focus globally in the healthcare sector. Seasonal influenza is an acute respiratory infection caused by influenza viruses which circulate in all parts of the world. Seasonally, it remains a persistent health threat and has been declared an epidemic in some states. Typical vaccines have been less effective against rapidly evolving pathogens such as influenza. A new class of vaccines based on nucleic acids, namely RNA, have recently been developed and show immense promise due to their robust nature, short manufacturing times and enhanced efficacy. Here we propose an RNA delivery system based on a supramolecular assembly approach for the vaccination of influenza A H1N1 strain. Specifically, a π-amphiphile will be used as the platform molecule for covalent RNA conjugation and delivery. A messenger RNA (mRNA) targeting the hemagglutinin (HA) gene from a model influenza virus strain will be employed as the therapeutic (H1N1/PR8-HA). The central π-amphiphile moiety will be functionalized with the mRNA strand via a redox responsive disulfide bond, and hydrophilic oligo-oxy aryl groups connected via a hydrogen bonding unit to promote self-assembly. Steric stabilization will be afforded to the surface decorated mRNA to protect from enzymatic hydrolysis in the complex biological environments, through co-assembly with an analogue π-amphiphile which has been alternatively decorated with poly(ethylene glycol) (PEG) chains. Efficient intracellular transport of the delivery vehicle to achieve optimum mRNA transfection will be achieved through the incorporation of a TAT-peptide on the PEG chain end. The therapeutic efficacy of the nanoassembly will be evaluated through transfection efficacy in macrophage cell lines. Overall, this proposal aims to lay the groundwork for extending the scope of RNA vaccines by exploring the potential of supramolecular assemblies as a delivery vector.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPRARNA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUPRARNA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

SpaTime_AnTB (2020)

Single-cell spatiotemporal analysis of Mycobacterium tuberculosis responses to antibiotics within host microenvironments

Read More